JP2019208562A - Volatile body and agent volatilizer - Google Patents

Abstract

To provide a volatile body that realizes an agent volatilizer with high interior properties, and such an agent volatilizer.SOLUTION: A volatile body 4 has a longitudinal shape, and is used by being inserted into a container 3 that has an opening at its top and stores a liquid agent 2 inside. The volatile body is composed of a transparent material.SELECTED DRAWING: Figure 1

Description

  The present invention relates to a volatilizer that volatilizes liquid chemicals having various volatility such as fragrances and deodorants, and a chemical volatilizer equipped with the volatilizer.

  A chemical volatilizer that volatilizes liquid chemicals naturally is widely used in order to eliminate the discomfort caused by the odor of the room and the interior of the car and create a comfortable space. As this type of chemical volatilizer, for example, Patent Document 1 discloses a device in which a plurality of rod-shaped volatilizers are inserted into a container containing a liquid chemical. In the drug volatilizer of Patent Document 1, a part of the lower end side of each volatilizer is immersed in the liquid drug, while a part of the upper end side of each volatilized body protrudes from the upper opening of the container, and the liquid drug in the container is removed. Scented up by each volatilizer and volatilized out of the container, producing an aromatic effect.

  In many cases, chemical volatilizers are installed in places that can be seen by people such as living rooms and entrances. In recent years, there is an increasing need for chemical volatilizers with improved interior properties. Therefore, natural materials such as rattan and plants, artificial flowers, resin sticks, etc. are mainly used for the volatilization body.

JP 2011-004867 A

  In this type of chemical volatilizer, the container is often made of transparent glass, and a plurality of volatilized bodies inserted into the container can be seen through from the outside of the container. At this time, the conventional volatilized body is opaque, and the portion of the volatilized body immersed in the liquid chemical appears to be largely refracted by light refraction, so the volatilized body may appear to be broken at the liquid chemical level. It looks bigger than it actually is. Therefore, when many volatilization bodies are inserted in a container, since many volatilization bodies give a cluttered impression in a narrow container, there exists a subject that the interior property of a chemical volatilizer is impaired.

  This invention is made | formed in order to solve the said subject, and it aims at providing the volatilization body and chemical | medical agent volatilizer which enable a chemical volatilizer with high interior property.

  The volatilized body of the present invention has a longitudinal shape, is used by being inserted into a container having an opening at the top and containing a liquid medicine inside, and is made of a transparent material. And

  In the volatilization body of this invention, it is preferable to consist of a colorless and transparent material.

  Moreover, in the volatilization body of this invention, it is preferable that they are glass or resin.

  Moreover, in the volatilization body of this invention, it is preferable that it is the same color or the same color as the color of a liquid chemical | medical agent.

  The volatilization body of the present invention preferably includes at least one groove formed on the outer periphery so as to extend in the longitudinal direction and / or a cavity formed so as to extend in the longitudinal direction inside.

  The chemical volatilizer of the present invention is characterized by comprising the volatilized body having the above-described configuration, and a container having an opening in the upper part and containing a liquid chemical inside.

  According to the present invention, since the volatilization body is formed of a transparent material, in a state where the volatilization body is inserted into the container containing the liquid medicine, the volatilization body and the liquid drug are transmitted due to the light transmittance of the volatilization body. It becomes difficult for light to be reflected and refracted at the boundary. Therefore, when the volatilized body is viewed from the outside of the container, the portion immersed in the liquid chemical of the volatilized body is not largely refracted, so the portion immersed in the liquid chemical of the volatilized body is the liquid chemical liquid. It is possible to suppress the appearance of being broken at the surface or being larger than the actual size. In addition, since the liquid drug passes through the volatilized body during the volatilization of the liquid drug, light is more transmitted through the liquid drug and light is less likely to be reflected / refracted at the boundary with the liquid drug. It is possible to make the volatilized body difficult to see. Therefore, even if many volatilization bodies are inserted in the container, the aesthetics of a chemical volatilizer can be improved and the interior property of a chemical volatilizer can be improved.

It is a longitudinal cross-sectional view of the chemical volatilizer which concerns on this embodiment. It is a cross-sectional view of the volatilization body which concerns on this embodiment. It is sectional drawing which shows schematically a cross section when the volatilization body of other embodiment sucks up a liquid chemical | medical agent. It is sectional drawing which shows schematically a cross section when the volatilization body of a comparative example sucks up a liquid chemical | medical agent. It is explanatory drawing explaining the contact angle of a droplet.

  Embodiments of the present invention will be described below with reference to the accompanying drawings. FIG. 1 shows a schematic configuration of a drug volatilizer 1 according to an embodiment of the present invention. The chemical volatilizer 1 includes a container 3 in which a liquid chemical 2 is accommodated and a plurality of volatilizers 4 inserted into the container 2. The plurality of volatilizers 4 are partially immersed in the liquid medicine 2 in the container 3 while a part on the upper end side is exposed on the container 2. The drug volatilizer 1 sucks up the liquid drug 2 in the container 3 by a plurality of volatilizers 4 and volatilizes it outside the container 3 so that the medicinal effect of the liquid drug 2 on the surrounding space where the drug volatilizer 1 is installed. Demonstrate.

  The liquid medicine 2 has volatility (medicine sustained release) and exhibits medicinal effects by gradually volatilizing the drug in the air. Examples of the liquid drug 2 include fragrances, deodorants, insect repellents and the like, but are not particularly limited, and depending on the purpose of use, perfumes, deodorant components, insect repellent components, coloring Fees and the like can be included alone or in combination. The solvent contained in the liquid medicine 2 is appropriately selected according to the type of additive used, and can be a hydrophilic solvent or a lipophilic solvent, or a mixture thereof. When the liquid medicine 2 contains a fragrance, it is preferable to contain at least a lipophilic solvent as a solvent in order to increase the scent strength. As the hydrophilic solvent, for example, water, ethanol, or a mixture thereof can be used. As the lipophilic solvent, for example, glycol ether or isoparaffinic solvent, or a mixture thereof can be used. In addition, in order to solubilize a fragrance | flavor, a deodorizing component, an insect repellent component, a coloring agent, etc., the liquid chemical | medical agent may contain the solubilizer.

  The container 3 is a bottomed container having an opening 30 in the upper portion and a space for storing the liquid medicine 2 therein. In the present embodiment, the container 3 includes a neck portion 31 having an opening 30, a shoulder portion 32 that continues to the neck portion 31, a hollow body portion 33 that continues to the shoulder portion 32, and a bottom portion 34 that continues to the lower portion of the body portion 33. It consists of and. The bottom portion 34 has a central portion that protrudes in a dome shape above the outer peripheral portion, and has a height that decreases from the central portion toward the outer peripheral portion. As a result, when the amount of the liquid medicine 2 in the container 3 becomes small with use, the liquid medicine 2 is stored in the outer peripheral portion of the bottom 34 having a low height, so that the remaining liquid medicine 2 is surely volatilized. The body 4 can suck up.

  In addition, the shape of the container 3 is not particularly limited, and containers having various shapes can be used as long as the container has an opening 30 in the upper portion and can accommodate the liquid medicine 2 therein. For example, the outer peripheral surface of the trunk portion 33 may be an uneven surface in which the unevenness is alternately repeated over the entire periphery.

  The container 3 is transparent or translucent. Further, the container 3 may be either colorless or colored. The term “translucent” means that the transparency is not completely transparent but has transparency that allows the inside to be visually recognized. Since the container 3 can visually recognize the inside of the container 3 from the outside, for example, the remaining amount of the liquid medicine 2 in the container 3 can be confirmed. The container 3 is preferably colorless and transparent in order to improve internal visibility. The material of the container 3 is not particularly limited, and for example, it can be made of glass or plastic, but from the viewpoint of aesthetics, it is preferably made of glass.

  The volatilization body 4 has a longitudinal shape, and in the present embodiment, has a rod shape. The longitudinal shape refers to a shape whose length in one direction is sufficiently longer than the length in a direction orthogonal to the one direction. The volatilization body 4 does not necessarily have a rod shape, and may have, for example, an elongated plate shape.

  The length (size in the longitudinal direction) of the volatilization body 4 is such that the upper end protrudes from the upper opening 30 of the container 2 and the lower end reaches the inner bottom surface (preferably the outer peripheral portion of the inner bottom surface) of the bottom 34 of the container 3. If it is, it will not be specifically limited, Depending on the magnitude | size of the container 3, it can be 110 mm or more and 190 mm or less, for example.

  The thickness of the volatilization body 4 is not particularly limited, but the thinner one is not conspicuous in appearance when the drug volatilizer 1 is visually recognized from the outside, and is preferable from the viewpoint of design, but is thin. Since it will become easy to bend when too large, it is preferable to set it as 1.0 mm or more and 4.0 mm or less. In addition, the thickness of the volatilization body 4 can be defined by the diameter of a circle in which the cross section of the volatilization body 4 is inscribed.

  As shown in FIG. 2, the volatilizer 4 is a fine channel that is a channel through which the liquid drug 2 is sucked up in the longitudinal direction so that the liquid drug 2 can be sucked up by capillary action as shown in FIG. 2. A plurality of streak-like grooves 40 are provided on the outer periphery at intervals in the circumferential direction. The volatilizing body 4 includes a shaft portion 41 and a plurality of protrusions 42 protruding from the outer peripheral surface of the shaft portion 41 and extending in the longitudinal direction on the outer peripheral surface of the shaft portion 41, and between the adjacent protrusions 42 in the circumferential direction. There is a groove 40 in the groove. The outer shape of the cross section of the shaft portion 41 is not necessarily circular, and may be various shapes such as an elliptical shape, a polygonal shape such as a triangular shape or a quadrangular shape. The shape of the protrusion 42 (the shape of the groove 40) is not particularly limited, but in the present embodiment, the plurality of protrusions 42 radially spread from the center of the shaft portion 41. Therefore, the interval (circumferential length) between the adjacent protrusions 42 gradually increases toward the top part 42A of the protrusions 42. In other words, the width of the groove 40 extends from the groove bottom 40A to the external space side. It gradually spreads as it heads.

  The width (width at the groove bottom 40A) W of the volatilization body 4 is not particularly limited, but is 0.01 mm or more and 0.15 mm or less so that the liquid medicine 2 can be quickly sucked up at room temperature. It is preferable that Moreover, although the depth (height of the protrusion 42 from the outer peripheral surface of the axial part 41) H of the volatilization body 4 is not specifically limited, If the groove 40 is too deep, the protrusion 42 will be easy to bend. On the other hand, since the liquid chemical | medical agent 2 which can be sucked up will decrease when the groove | channel 40 is too shallow, it is preferable to set it as 0.1 mm or more and 1.0 mm or less.

  The volatilizer 4 may include a flow path for another liquid drug 2 in place of the plurality of grooves 40 or in addition to the plurality of grooves 40 as long as the liquid drug 2 can be sucked up appropriately by capillary action. For example, by making the volatilization body 4 have a hollow structure, the cavity 43 extending in the longitudinal direction inside the volatilization body 4 can be used as a flow path for the liquid medicine 2. In this case, a fine groove may be further provided on the inner peripheral surface of the volatilizing body 4.

  As the liquid medicine 2 passes through the volatilization body 4 by sucking up the liquid medicine 2 by the volatilization body 4, the details will be described later, but light is transmitted through the liquid medicine 2 and light at the boundary with the liquid medicine 2. Is less likely to be reflected and refracted, so that the volatilization body 4 can be made difficult to see in the liquid medicine 2.

  The volatilization body 4 having the above-described configuration is formed of a transparent material. The transparent material forming the volatilization body 4 may be either colorless or colored. Since the volatilization body 4 is formed of a transparent material, the volatilization body 4 has light permeability, so that it is difficult for light to be reflected and refracted at the boundary with the liquid medicine 2 in the liquid medicine 2. . Therefore, when the volatilization body 4 is viewed from the outside of the container 2, the portion of the volatilization body 4 that is immersed in the liquid medicine 2 does not appear to be largely refracted. It is suppressed that the portion looks broken at the liquid surface of the liquid medicine 2 or looks larger than the actual size.

  Moreover, when the volatilization body 4 is formed of a transparent material, the outer surface of the volatilization body 4 has a large number of surfaces that reflect light due to the plurality of grooves 40 on the outer periphery. Looks like. Thereby, even when the part immersed in the liquid chemical | medical agent 2 of the volatilization body 4 looks somewhat refracted when the volatilization body 4 is seen from the outer side of the container 2, many volatilization bodies 4 in the container 2 are seen. Rather than giving the impression that the container 2 is cluttered, the container 2 gives the impression that the container 2 shines brightly. Therefore, since the beauty | look of the chemical volatilizer 1 improves, the interior property of the chemical volatilizer 1 is improved.

  As a transparent material for forming the volatilization body 4, for example, glass or transparent resin can be used. Examples of the transparent resin include polycarbonate, acrylic resin, polypropylene, polyethylene, low density polyethylene, vinylidene fluoride, Polyamide, polystyrene, vinyl chloride and the like can be preferably used.

  In the case where the liquid drug 2 is colored, the volatilizer 4 is preferably the same color or a similar color as the liquid drug 2. Thereby, the volatilization body 4 becomes easy to assimilate with the liquid chemical | medical agent 2, and the volatilization body 4 can be made hard to see in the liquid chemical | medical agent 2 more. Similar colors refer to similar colors, colors that are adjacent to each other in the hue circle or colors that are close to each other, and examples include blue and light blue, orange and yellow, and green and yellow-green. Can do.

  The volatilization body 4 can be formed by a general molding method (for example, extrusion molding for a resin, for example, draw molding for glass, for example) using the material for forming the volatilization body 4 described above. The volatilization body 4 is preferably formed by extrusion molding or the like, and is preferably constituted of a single object (one rod-like body or plate-like body), and is a dense body with no or almost no gaps or holes. preferable. Thereby, since the volatilization body 4 is not substantially impregnated with the liquid medicine 2 inside, the volatilization body 4 is not in a state of holding the liquid medicine 2 excessively, and when the liquid medicine 2 disappears from the container 3, Since the liquid chemical 2 that the volatilizer 4 also immediately holds is lost, the end of use can be easily grasped. Moreover, in the volatilization body 4, since the flow path through which the liquid chemical | medical agent 2 passes other than the outer periphery groove | channel 40 and the internal cavity 43 can be eliminated, the suction speed of the liquid chemical | medical agent 2 by the volatilization body 4 is hold | maintained at a desired setting speed. be able to.

  As mentioned above, according to the chemical | medical agent volatilizer 1 using the volatilization body 4 and the said volatilization body 4 which were mentioned above, since the volatilization body 4 is formed with the transparent material, it is liquid by the light transmittance of the volatilization body 4. Since the light is less likely to be reflected and refracted at the boundary with the liquid medicine 2 in the medicine 2, when the volatilization body 4 is viewed from the outside of the container 2, the portion immersed in the liquid medicine 2 of the volatilization body 4 is It can be prevented that the light is greatly refracted. In addition, since the volatilization body 4 appears to shine brightly in the container 2 due to the plurality of grooves 40 on the outer periphery, the aesthetic appearance of the chemical volatilizer 1 can be improved even if a large number of the volatilization bodies 4 are inserted into the container 2. The interior of the chemical volatilizer 1 can be enhanced. Further, even if the liquid medicine 2 is colored, the colored liquid medicine 2 sucked up in each groove 40 becomes difficult to visually recognize because the volatilizer 4 shines brightly. Therefore, it can be seen that the volatilization body 4 does not change so much as before the liquid medicine 2 is sucked up, and the volatilization body 4 does not appear to be wet with the liquid medicine 2. In addition, if the volatilization body 4 is formed with a colorless and transparent material, the said effect can be suitably exhibited irrespective of the color of the liquid chemical | medical agent 2. FIG.

  In addition, the volatilization body 4 passes through the outer peripheral groove 40 and / or the internal cavity 43 by sucking up, so that light is transmitted more in the liquid medicine 2 and at the boundary with the liquid medicine 2. Since it becomes difficult for light to be reflected and refracted, the volatilization body 4 can be made difficult to see in the liquid medicine 2. Therefore, even if many volatilization bodies 4 are inserted in the container 2, the volatilization body 4 can be almost assimilated with the liquid medicine 2, so that the inside of the container 2 is not cluttered by the many volatilization bodies 4. Therefore, the beauty | look of the chemical volatilizer 1 can be improved further and the interior property of the chemical volatilizer 1 can further be improved. Even if the liquid drug 2 is colored, the volatilizer 4 is mostly the same color as the external liquid drug 2 due to the liquid drug 2 passing through the outer peripheral groove 40 and / or the internal cavity 43. Therefore, the volatilization body 4 becomes difficult to see in the liquid medicine 2. Further, when the volatilizing body 4 is the same color or the same color as the color of the liquid medicine 2, the volatilizing body 4 can be made more difficult to see in the liquid medicine 2.

  As mentioned above, although one Embodiment of this invention was described, this invention is not limited to the said embodiment, A various change is possible unless it deviates from the meaning.

  For example, in the above embodiment, the plurality of protrusions 42 have the same height H, but a plurality of kinds of protrusions having different heights may be combined. Further, the top portion 42A of each protrusion 42 may be branched into, for example, a Y shape in a cross sectional view.

  Moreover, in the said embodiment, the volatilization body 4 may be formed with the material with high affinity with the liquid chemical | medical agent 2. FIG. Since the volatilizer 4 is formed of a material having high affinity with the liquid drug 2, when the liquid drug 2 is sucked up by the respective grooves 40 of the volatilizer 4, the liquid drug 2 is deposited on the surface of the groove 40. It spreads so that the area where the liquid medicine 2 comes into contact with the surface of the groove 40 increases. Therefore, as shown in FIG. 3, when the liquid medicine 2 is sucked up in each groove 40 of the volatilization body 4, the liquid surface height of the liquid medicine 2 is greater than the depth (height of the protrusion 42) H of the groove 40. The liquid level of the liquid medicine 2 does not rise to the outer space side than the outer edge of the groove 40 (the top portion 42A of the protrusion 42). Therefore, when a hand, clothes, a curtain, or the like touches the upper end side portion exposed from the container 2 of the volatilizer 4, the top portion 42A of the protrusion 42 first touches the hand, and the liquid medicine 2 in the groove 40 becomes a hand. It becomes difficult to adhere to.

  If the volatilizer 4 is formed of a material having low affinity with the liquid drug 2, the liquid drug 2 is repelled on the surface of the groove 40 when the liquid drug 2 is sucked up by each groove 40 of the volatilizer 4. As a result, the liquid medicine 2 has a smaller area of contact with the surface of the groove 40. Therefore, as shown in FIG. 4, when the liquid medicine 2 is sucked up in each groove 40 of the volatilizer 4, the liquid level of the liquid medicine 2 becomes higher than the height H of the protrusion 42, and the liquid medicine 2 The liquid level rises to the outside space side from the top 42A of the protrusion 42. Therefore, when a hand, clothes, a curtain, etc. touch the part of the volatilization body 4 exposed from the container 2, the liquid chemical | medical agent 2 in the groove | channel 40 becomes easy to adhere to a hand etc.

  As the material having high affinity with the liquid drug 2, the liquid drug 2 has a contact angle α of 90 ° or less, preferably 70 ° or less, more preferably 50 ° or less, as shown in FIG. More preferably, the material is 30 ° or less, and more preferably 10 ° or less. This contact angle α is made of the material used for the volatilizer 4, and after removing dirt on the surface of the thin plate 5 (size: 60 mm × 20 mm, thickness: about 5 mm) having a flat surface, for example, using a micropipette. A liquid drug 2 droplet of about 6 μL is deposited on the surface of the thin plate 5, and the contact angle α of the liquid droplet after 1000 ms is measured with a contact angle meter (Kyowa Interface Chemical Co., Ltd .: DropMaster 500, measurement analysis integrated software: FAMAS). can do.

1 Drug volatilizer 2 Liquid drug 3 Container 4 Volatilizer 40 Groove

Claims (6)

It is a volatilizing body that is used by being inserted into a container that has a longitudinal shape, has an opening at the top, and contains a liquid medicine inside,
Volatile body made of transparent material.   The volatilization body of Claim 1 which consists of a colorless and transparent material.   The volatilization body according to claim 1 or 2 made of glass or resin.   The volatilization body in any one of Claims 1-3 which is the same color or the same color as the color of a liquid chemical | medical agent.   The volatilization body in any one of Claims 1-4 provided with the at least 1 groove | channel formed in the outer periphery so that it may extend in a longitudinal direction, and / or the cavity formed so that it might extend in a longitudinal direction inside. The volatilization body according to any one of claims 1 to 5,
A drug volatilizer comprising: a container having an opening in the upper part and containing a liquid drug therein.